Because activation of the KRAS and TP53 pathways is associated with mutations in the KRAS and TP53 genes21,22, we investigated whether there is a correlation between diseases with heavy mutation burden in these genes and diseases with higher correlation between tumor and cell line, with the assumption that cell lines derived from mutated tumors maintain those mutations. This evidence concerns the gene TP53 and neoplasm.